While preliminary data suggest a potential association, further studies are needed to fully understand the mechanisms at play and to develop strategies for minimizing UTI risk in patients using semaglutide
The remaining TRIUMPH trials (TRIUMPH-2 in obesity + T2D, TRIUMPH-3 in cardiovascular disease, TRIUMPH-OSA in sleep apnea, TRIUMPH-5 in liver disease, TRIUMPH-6 in chronic low back pain) will expand the label but are not required for the initial obesity approval
At Ventegra, we believe healthcare should be a societal goodaccessible, sustainable, and smartly managed
and Akkermansia spp., effectively moderating the microbial imbalance and colonic inflammation triggered by experimental colitis, alongside preserving the integrity of the mucus barrier (Ke et al., 2021
The committee plans to further discusses the issue at a meeting in April